• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA: Don’t use smartwatches, smart rings to measure blood glucose

February 22, 2024 By Sean Whooley

Apple Watch continuous glucose monitoring CGM
[Photo by Simon Daoudi on Unsplash]
The FDA issued a warning to consumers, patients, caregivers and providers around using certain technology to measure blood glucose.

In the warning, the agency outlined the risks related to using smartwatches or smart rings for this purpose. Such devices may claim to measure blood glucose levels without piercing the skin. These devices are different from smartwatch applications that display data from FDA-authorized blood glucose measuring devices like CGMs.

The FDA says that, to date, it has not authorized, cleared or approved any smartwatch or smart ring intended to measure or estimate these values on its own. People with diabetes receiving inaccurate blood glucose measurements can experience errors in their diabetes management. That includes incorrect insulin dosing, sulfonylureas or other medications.

According to the FDA notice, consumers should not buy or use these devices that claim to measure blood glucose levels. Some may be sold through online marketplaces or directly from sellers. The agency wants to raise awareness that the FDA has yet to review the safety and effectiveness of these devices.

The FDA said it continues to alert consumers about the issue and raise public awareness. It plans to keep the public informed if new information becomes available.

While no device has FDA authorization, non-invasive glucose monitoring has become a target. Large tech companies like Samsung and Apple reportedly aim to offer glucose monitoring through their smart devices. Other, more diabetes-focused companies like Know Labs and Nemaura Medical, also have devices under development for this purpose. Neither have FDA authorization yet, though.

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology Tagged With: FDA

IN CASE YOU MISSED IT

  • Medtrum introduces 300-unit tubeless insulin pump
  • Baxter reports positive smart infusion pump, EMR integration data
  • Dexcom to cease G6 CGM production next year, transition fully to G7
  • Modular Medical prices $4.7M public offering
  • Medtronic studies highlight MiniMed 780G’s cost-effectiveness

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS